🔍
Search Results - clinical+and+disease+specializations+%3e+musculoskeletal+%3e+muscle+atrophy
2
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Dendrimer-conjugated GCPII Inhibitors to Delay Loss of Muscle Mass and Strength
Value Proposition· GCPII inhibitor has a low IC50 (<5 nM), suggesting greater potency and less systemic toxicity.· Functional improvements after treatment include 95% preservation of muscle mass, 96% preservation of grip strength, 25% greater isometric force.· Decreased decline in neuromuscular transmission compared to control. Technology...
Published: 3/13/2026
|
Inventor(s):
Barbara Slusher
,
Yu Su
,
Kannan Rangaramanujam
Keywords(s):
Category(s):
Clinical and Disease Specializations > Musculoskeletal > Muscle Atrophy
,
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
Muscular Dystrophy Cell Lines
Unmet NeedFacioscapulohumeral muscular dystrophy (FSHD) is a complex neuromuscular disorder affecting 1 in 20,000 individuals. The disease is characterized by progressive wasting of facial, upper arm and shoulder girdle muscles. FSHD has variable age of onset, ranging from infant to late adult; and approximately one-third of patients lose the ability...
Published: 3/13/2026
|
Inventor(s):
Kathryn Wagner
Keywords(s):
Cell Lines
,
CNS and Neurological Disorders
,
Discovery/Research Tools
,
Disease Indication
,
Human Cell Lines
,
In Vitro Research Tool
,
Muscular Dystrophy
Category(s):
Technology Classifications > Research Tools > Cell Lines
,
Clinical and Disease Specializations > Musculoskeletal > Muscle Atrophy
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum
